All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying and recording, or by any information storage and retrieval system, without permission in writing from the publishers. Malaria. And presumably these had some executive power behind them; and they resulted in some action. A follow-up symposium to the one organized by the British Society for Immunology was held by the British Society for Parasitology, in 1968, on Immunity to Parasites: again that meeting attempted to focus on the problems with which we are concerned here: that is, the question of immunity. There was also a recent meeting on leishmaniasis arranged by the Wellcome Trust, and one on Trypanosomiasis and Leishntaniasis arranged by this foundation; and there have been other such meetings in other countries. But none of these have focused discussion quite so aptly as I hope this symposium will do, under the title chosen for this meeting.
Introduction

R. R. A. COOMBS
In the past a number of books have been published on the subject of this symposium, but perhaps none has focused so closely on the actual mechanisms by which parasites survive in their immunized hosts, as opposed to the general immunology of infestation. The first book on this subject was that of Taliaferro And presumably these had some executive power behind them; and they resulted in some action.
A follow-up symposium to the one organized by the British Society for Immunology was held by the British Society for Parasitology, in 1968, on Immunity to Parasites: again that meeting attempted to focus on the problems with which we are concerned here: that is, the question of immunity. There was also a recent meeting on leishmaniasis arranged by the Wellcome Trust, and one on Trypanosomiasis and Leishntaniasis arranged by this foundation; and there have been other such meetings in other countries. But none of these have focused discussion quite so aptly as I hope this symposium will do, under the title chosen for this meeting.
There is one thing which these earlier meetings did not achieve, and I do not expect this one will either! This is something I feel strongly about, but which is extremely difficult to implement. Meetings such as these begin with three professional types : parasitologists; specialists in tropical medicine ; and immunologists. Thesespecialistsare brought into discussion, but to my mind what is needed now more than ever and is so difficult to achieve (and there are many reasons for this) is to bring people actually to work together. In this particular field this is an extremely difficult matter, especially when it means going to tropical countries, organizing an interchange of workers, and so on. We should consider the difficulties and make realistic suggestions about how to overcome them. I say this because it is clear that, despite the relative lack of attention given to immunoprophylaxis in general, immunoprophylaxis is probably the most important contribution that immunology makes to medicine. I think it is certain that immunoprophylaxis in general has by no means yet reached its full potential and that in the next 20 years we shall have successful immunoprophylaxis of many protozoal and other parasitic diseases. 1 say this in the full realization of the many problems and difficulties that have to be overcome, many of which we shall be discussing.
People working in this area are very fortunate, in fact: in the first place, how nice it is to feel that one's work is important medically, socially and economically; and this holds very much in this particular field. We are aZso fortunate because scientifically it is also so fascinating and challenging. In this symposium we shall indulge ourselves a little, thinking about the fascinating interplay between the parasite and the full repertoire of the immune or allergic reactivity of the host. With the weight of scientific endeavour ready to promote and exploit this allergic reactivity, there seems to be almost no limit to what one could do to induce, enhance or ablate, if necessary, the allergic reactivity of the individual, and thus we ought to be able to find a way to get ahead of the parasite and to counter the various tricks that it gets up to. We hope in this meeting to analyse the mechanisms by which, at the moment, the parasites hold the trump cards, and to see what can be done, prophylactically or therapeutically, to overtrump them! 1 think we ought to be able to outwit the parasite.
Resistance to microorganisms, including animal parasites, is most frequently attributable to innate (natural) immunity which is usually characteristic of the species and is not dependent on previous discernible exposure to the pathogen. The importance of such innate resistance is illustrated by the fact that, although about 8000 species of protozoa parasitic for various hosts are known, only about 20 of these are significant pathogens of man (Table 1) . Very little is known about the factors that determine host-parasite compatibility. There are, however, some instances in which the mechanisms of innate resistance to parasitic infection have been analysed in some detail. For example, malarial susceptibility and resistance are not dependent on serum factors but correlate with the presence or absence of surface receptors for the specific parasite on the host's red cells (Butcher et al. 1973) ; also, the single gene mutation responsible for the production of sickle-cell haemoglobin so alters the red cell environment as to confer partial resistance to Plasmodium falciparum malaria in man (Allison 1963) . Leishmania organisms are readily killed by activated macrophages of resistant hosts, but survive in similar cells from susceptible hosts (Mauel et al. 1973) . The significance of specific acquired immunity in parasitic infections has long been disputed because clinically effective responses, such as occur in many bacterial and viral diseases, are rarely seen. However, there is now abundant evidence, summarized in this chapter, that animal parasites are immunogenic and sensitize the host's conventional immune effector pathways. It is equally clear that parasites have evolved means of evading the potentially lethal consequences of immunization. The mechanisms which permit parasites to survive can only be evaluated in relation to the specific immune responses which the particular infection evokes in the host.
CLINICAL MANIFESTATIONS OF ACQUIRED IMMUNlTY TO PARASITIC INFECTIONS
The clinical manifestations of acquired specific resistance are frequently absent or equivocal in parasite infections. Three categories of clinical response can be distinguished (see Cohen 1974) .
(i) Absence of an effective immune response
Human subjects do not usually develop effective immunity against African trypanosomes (Trypanosoma brucei rhodesiense or T, b. gambiense), although healthy carriers are described, nor is there discernible immunity in primary amoebic meningoencephalitis. Individuals with South American trypanosomiasis (Chagas' disease; T. cruzi) may harbour the parasites for life, often with progressive signs of debilitating disease. The same is true of human visceral leishmaniasis in which records of spontaneous cure are rare and acquired immunity usually becomes manifest only after drug therapy. Human subjects seem to remain fully susceptible to amoebiasis even after recovery from an earlier infection. Many nematodes, including those causing visceral larva migrans and hookworm infections, persist in man for very long periods.
(ii) Non-sterilizing immunity Many parasitic infections induce an immune response which results in resistance to specific challenge, but is associated with persistence of the parasite at relatively low density. This type of response is characteristic of many helminth infections, such as schistosomiasis and trichiniasis. In the case of protozoa, this phenomenon of clinical immunity with persistence of parasites has been referred to as 'premunition' and its features have been described in detail by Sergent (1963) . Premunition is characteristic of many human, simian and avian malarias. In some, such as P. fakiparum malaria in man, clinical resistance accompanies periodically detectable parasitaemia, while in others, such as P. inui in the rhesus monkey, parasitaemia may persist with only minor fluctuations over many years. Other examples of premunition are seen in the chronic relapsing form of human cutaneous leishmaniasis, in Trichomonas foetus infections in bulls, Trypanosoma cruzi in mice, many species of Babesia and Theileria in cattle, avian coccidiosis, and toxoplasmosis in mice and other animals. Wild African ungulates may harbour potentially pathogenic trypanosomes, such as T. b. rhodesiense, without showing detectable symptoms, but the role of acquired immunity in this situation has not been established.
(iii) Sterilizing immunity
Immunity to some parasitic infections is associated with clinical cure, complete elimination of the parasite and life-long specific resistance to challenge. This probably occurs in human cutaneous leishmaniasis, trypanosomiasis in the N'Dama breed of short-horn cattle, T. lewisi infections of the rat and in Theileria parva infections of cattle indigenous to East Africa, although in this instance prentunition may follow infection in field conditions. Among the various species of malaria parasites, P . berghei in the rat, P. berghei yoelii in the mouse, and P . cynomolgi bastianellii in the rhesus monkey, induce a sterilizing immunity.
The pattern of acquired immunity is not constant for a given parasite, but shows wide variation in different hosts. P . knowlesi, for example, produces fulminating and rapidly fatal malaria in the rhesus monkey, Macuca mulatta, but premunition associated with mild intermittent parasitaeniia in the Kra monkey, M . fascicularis. P. berghei induces sterile immunity in the rat, but a rapidly fatal infection in mice. T. vivax is frequently lethal for large-humped Zebu cattle, while short-horned cattle from a herd exposed to infection over many generations show a sterilizing immune response. The same inoculum of Leishmania tropica may cause a transient lesion in one person and a chronic, relapsing infection in another. The extent to which acquired immunity determines these different clinical responses to the same pathogen has not been established.
Acquired immunity to parasites, whether associated with premunition or a sterilizing response, is, in general, species-and strain-specific. This has, for example, been established in some detail in human and experimental malaria and African trypanosomiasis. Acquired immunity in malaria is also stagespecific, since resistance to erythrocytic forms does not modify the exo-erythrocytic development of parasites in man, chimpanzee or monkey, but suppresses the subsequent phase of erythrocytic development. Conversely, birds or rodents immunized against sporozoites are fully susceptible to blood forms of the same parasite. The immunity induced by sporozoites may show broad specificity, since, for example, immunization with sporozoites of P. berghei protects against challenge with the sporozoites of P . chabaudi or P. vinckei (Nussenzweig et al. 1969) .
THE IMMUNE RESPONSE TO PARASITIC INFECTIONS
The fact that clinical evidence for acquired immunity is often indecisive in protozoal infections has led to the belief that protozoa are poorly immunogenic. There is no basis whatever for this view, since specific antibody has been demonstrated in every infection adequately studied. It is clear, however, that the antibody in many instances has little or no protective function.
(i) NonspeciJic intmunoglobulin production
The amount of immunoglobulin is considerably increased in many protozoal infections, but only a small proportion of it may have demonstrable affinity for the pathogen (reviewed by Cohen 1974). The interesting suggestion has been made that nonspecific Ig synthesis may result from stimulation of B lymphocytes by interaction with antigen-antibody complexes through receptors for the third component of complement (C3) on their surface membranes (Nussenzweig & Pincus 1972). However, it is difficult to explain the frequent class specificity of nonspecific Ig on this basis.
West African adults living in hyperendemic malarial areas show elevated levels of IgG and especially of IgM. In these clinically immune subjects the rate of albumin synthesis is similar to that in normal Europeans, but IgG production is almost seven times greater. IgG synthesis was reduced by about a third after malarial prophylactic therapy, yet only 5 of immune adult IgG combines specifically with P. fakiparum antigens. Some of the remaining IgG might be antibody against other serological variants of P. fakiparum or against soluble malarial antigens present in serum. Nevertheless, it seems that chronic malarial infection stimulates the production of nonspecific Ig which accounts for the unusually high incidence of autoantibodies, cold agglutinins and probably also immunoconglutinins in hypergammaglobulinaemic sera from subjects exposed to chronic malaria.
An even greater increase in gammaglobulin, mainly of IgG, is seen in visceral leishmaniasis. Concentrations above 5g /lo0 ml are not unusual in human patients. The characterization of this IgG is incomplete, but a major part appears not to be specific antibody, and the stimulus for its production remains an intriguing and unresolved problem. Equally remarkable is the elevation of IgM in African trypanosomiasis; this is of diagnostic value, since if levels are normal, trypanosomal infection can almost certainly be ruled out.
The IgM contains trypanosome-agglutinating antibody, as well as antiglobulin and heterophil antibodies and increased amounts of naturally occurring ZgM antibodies. The IgM concentration may remain high long after exposure to infection has ceased and when tests for trypanocidal antibody are negative; it seems, therefore, that much of the IgM produced in trypanosomiasis is nonspecific, and it is possible that the parasite in some way prevents the induction of IgG, which normally extinguishes the IgM response. In experimental infections (e.g. T. equiperdum in rabbits) about 5 % of the total IgM may be in monomeric (7s) form. Rabbits infected with T. brucei also show a striking increase in immunoconglutinins.
(ii) Specific antibody
In all parasitic diseases investigated, specific antibody can be demonstrated by a variety of techniques ( Table 2) . Many of these tests have been useful in diagnosis and in epidemiological surveys of both protozoal and helminth infections. In general these reactions correlate poorly with the clinical immune status, which indicates that, in addition to the nonspecific Ig discussed above, parasitic infections stimulate the production of specific antibody having no protective function. Such antibody may be directed against serotypes of the organism present earlier in the infection, against soluble serum antigens, or against various metabolites and degradation products not present on the surface of the intact living parasite and therefore irrelevant to its specific destruction.
(iii) Demonstration of protective antibody
Since as a general rule parasites sensitize the host's immune system, their survival must depend upon evading effector immune mechanisms. Our knowledge of how this is achieved will be discussed during this symposium. Whatever THE IMMUNE RESPONSE TO PARASITES 9 the mechanisms involved, it is apparent that factors favouring survival of parasites in natural infections may also operate in experimental situations designed to demonstrate a protective action of parasitic antibody, by means of the classical methods of the passive transfer of immune serum or of sensitized cells. Passive immunity can, as expected, be shown in those diseases associated clinically with a sterilizing immune response, such as rodent trypanosomiasis, rodent malaria and cutaneous leishmaniasis ( Table 3) . In other protozoal motility, metabolism, respiration and multiplication of parasites, have revealed parasiticidal antibody in a somewhat wider range of infections including malaria, African trypanosomiasis, schistosomiasis and nematode infections, all of which induce a non-sterilizing immunity in vivo (Table 4) . These in vitro studies have, in some instances, disclosed the nature of the immune effector mechanisms induced in the parasitized host.
(iv) Mechanisms of specijc acquired immunity in parasitic infections
Adaptive immune responses are initiated by the interaction of antigen with specific receptors on the surfaces of lymphoid cells, which are now recognized as belonging to two major classes. T lymphocytes undergo transformation and mitosis, so generating a population of cells specifically reactive with the inducing antigen ; B lymphocytes differentiate into plasma cells which secrete humoral antibody, but this process usually requires cooperation with T cells. The effector mechanisms generated by these cellular responses therefore fall into two major categories : those mediated by specific humoral antibody, and those mediated by specifically sensitized T lymphocytes (cell-mediated immunity). While it is true that antibody may, in certain circumstances, act independently of cells (Reactions 1 and 2, Table 5) and that certain specific cell-mediated reactions are independent of antibody (Reaction 6, Table 5 ), there are also several specific immune effector mechanisms which require the interaction of humoral antibody with cells such as macrophages (Reaction 3, Table 5 ), K (killer) cells (Reaction 4, Table 5), or mast cells (Reaction 6, Table 5 ). In addition, the interaction of antigen with T lymphocytes may lead to the activation of macrophages or the release of lymphotoxins and so damage cells in the locality which do not carry the specific antigen (Reactions 7 and 8, Table 5 ).
The detailed mechanisms of immunity to parasites have been elucidated in only a few diseases. The role of serum antibody in acquired immunity to malaria was established by passive transfer tests in human and experimental infections. Protective antibody appeared to act against either matuie schizonts or extracellular nierozoites and was present in the IgG fraction of human immune serum (Cohen et al. 1961) . In vitro experiments with P. knowlesi showed that immune serum has no effect upon the growth of intracellular parasites, but inhibits the cycle of development which follows schizogony (Fig. 1 *) . This effect is species-specific, is not complement-dependent and in the sera studied was associated with IgM and IgG but not IgA or IgE . The failure to demonstrate activity in monkey IgE is of interest * Seep. 13 
4.
.
6.
7. a 8."
Mediators
1
Activated macrophage Nonspecific mechanism. P, parasite; Ig, specific antibody; C, complement. 
Malaria
Nippostvongylus brasilicwsis
African tiypanosomiasis Rodent trypanosomiasis Schistosomula (in vitro)
FIG. 1.
The incorporation in vifro of tritiated leucine into P. knowbsi parasites and into nonparasitized red cells in normal and immune rhesus monkey sera. The period of schizogony is indicated by arrows. P, % red cells parasitized. R, % parasites which are young ring forms in flasks containing normal serum. (Cohen et a / . 1969.) because IgE is abundant in human and monkey parasitic infections and this, together with the common occurrence of immediate type sensitivity, had suggested a possible protective role for IgE in protozoal infections (Reaction 5, Table 5 ). Protective malarial antibody seems to act upon merozoites when these enter the plasma and prevent the reinvasion of red cells, perhaps by blocking the attachment of parasites to the erythrocyte membrane (Reaction 1, Table 5 ). Inhibitory antibody assayed in vitro is directed predominantly against those antigenic variants that have produced patent infections. However, antibody inhibitory for other variants is also present at lower titre and is associated with clinical immunity on challenge with such variants (Butcher & Cohen 1972 ). This explains why P. knowlesi parasites which arise by antigenic variation during the course of chronic infection produce mild parasitaemia in the host and yet are fully virulent in normal monkeys.
Passive immunization in trypanosomiasis (for example, T. gambiense in mice) provides variant-specific protection and may also prevent relapse and death if the dose of serum is large and the parasite challenge small-circumstances which appear to inhibit the subsequent appearance of antigenic variants (Watkins 1964) . A protective antibody specific for T. brucei was recognized in 1902 by Laveran & Mesnil(l9 12) in sera of infected sheep and goats. This observation later provided the basis for a neutralization test in which trypanosomes are mixed with serum in vitro and inactivation of the parasites is assessed by inoculation into mice. The neutralizing antibody is complement-dependent (Reaction 2, Table 5 ) and has species-and strain-specificity. The in vitro measurement of respiratory inhibition in trypanosomes depends upon antibody which has species-specificity and this test, done with sera from relatively resistant hosts, shows correlation with the clinical immune status.
Acquired immunity to T. lewisi can be passively transferred by immune serum which contains complement-dependent trypanocidal antibodies that are absorbed by living trypanosomes (Reaction 2, Table 5 ). In addition, immune sera in some infections contain a substance called ablastin, which is associated with y,-globulin, inhibits the in vivo and in vitro reproduction of the flagellate, but has no apparent effect upon its viability or motility and cannot be removed from immune serum by repeated absorption with living trypanosomes, suggesting that it has a low affinity. The separate identity of ablastin and trypanocidal antibodies is a matter of controversy. The in vitro growth of cultured or bloodstream forms of T. Iewisi is inhibited by homologous antisera but not by antisera raised against the non-corresponding form.
Cutaneous leishmaniasis of the guinea pig provides an experimental model for human oriental sore. The lesion caused by L. enriettii heals spontaneously, is associated with delayed hypersensitivity, and is followed by long-lasting immunity to reinfection. Delayed hypersensitivity can be passively transferred by lymphoid cells ; leishmania1 antigens transform lymphocytes in vitro and inhibit macrophage migration ; while the resistance of mice to infection with L. tropica is impaired after thymectomy (Preston et al. 1972) . On the basis of these findings it has been postulated that the human lesion characteristic of oriental sore is limited by cell-mediated immunity (Reaction 6, Table 5 ) and that a specific deficiency of this response results in the diffuse cutaneous and locally spreading lupoid forms of leishmaniasis (Turk & Bryceson 1971) . In this regard it is significant that the potentially fatal human visceral leishmaniasis (kala-azar) is not associated with cell-mediated immunity until the disease is cured by chemotherapy.
Attempts have been made to elucidate the mechanism of immunity to leishmaniasis by means of in vitro culture systems. Lymphocytes from sensitized animals (Reaction 6, Table 5 ) were reported to destroy monolayers of parasitized macrophages (Bryceson et al. 1970) , but under the same experimental conditions normal lymphocytes produced a comparable effect; this was attributed to adverse conditions in crowded cultures (Mauel et al. 1974) . Further experiments by Mauel and his collaborators have shown that neither peritoneal exudate cells from immune guinea pigs nor leishmania-activated macrophages shown to kill listeria organisms (Reaction 8, Table 5 ) are cytotoxic for intracellular L. enriettii organisms (see Mauel et al., this volume, .
Although serum antibodies may directly initiate some protective immune responses in parasitic diseases, their action in vivo must certainly be enhanced by a synergistic action with cells (Reactions 3 and 4, Table 5 ). In malaria and trypanosomiasis, the phagocytic activity of macrophages has long been recognized and the role of specific antibody in promoting ingestion of parasites by macrophages has been demonstrated in vitro and in vivo. Synergism between cells and antibody is also suggested by the finding that immune splenic cells confer greater protection than serum when passively transferred to rats challenged with P. berghei (Phillips 1970) . Similarly, the antimalarial action of passively transferred immune serum is diminished if the normal recipients have been previously splenectomized (Zuckerman et al. 1973) .
The importance of activated macrophages (Reaction 8, Table 5 ) in malarial immunity may explain the discrepant results of passive immunization experiments. Thus, immune IgG induced rapid elimination of parasites in West African children with severe infections yet equivalent doses of IgG from immune rhesus monkeys did not consistently inhibit parasitaemia in normal monkeys challenged with only 50 P . knowlesi parasites . Similarly, the multiplication of Toxoplasma gondii within macrophages is inhibited when these cells are derived from immunized hosts and this effect is enhanced by immune serum (Vischer & Suter 1954) .
In schistosomiasis, serum from monkeys immune to Schistosoma mansoni contains IgG antibodies which, in the presence of complement, kill young schistosomula maintained in culture (Clegg & Smithers 1972) . However, resistance to challenge, which occurs after natural infections, cannot be passively transferred with immune serum, which suggests that in vivo antibody may act synergistically with cells to produce specific immunity (? Reactions 3 and 4, Table 5 ).
In rats infected by the nematode Nippostrongylus brasiliensis, antibodies in the absence of complement reduce the metabolisni of the worms, inhibit their secretion of some enzymes, and cause cellular damage to the worm, especially of the gut and reproductive tract (Ogilvie & Jones 1973) . The expulsion of the worms is not, however, induced by antibody alone and requires synergistic action with cells, which can be eliminated by irradiation or neonatal thymectomy of the host or by the administration of antilymphocyte serum (? Reaction 7, Table 4 ). The role of IgE-mediated responses (Reaction 5, Table 3) in the expulsion of the nematode is controversial.
SUMMARY AND CONCLUSIONS
The clinical evidence of acquired immunity is often indecisive in parasitic infections and frequently takes the form of specific resistance to challenge associated with persistence of parasites at relatively low density. This fact has prompted the belief that parasites are poorly immunogenic, but there is no basis for this view, since specific antibody has been demonstrated by a variety of methods in every infection adequately studied. The detection of specific antibody has been useful in clinical diagnosis and in epidemiological studies, but in general it correlates poorly with the clinical immune status. This indicates that much of the specific antibody formed in response to parasitic infections has no protective effect.
The factors that allow parasites to survive in the immunized host have been found also to be effective in passive transfer experiments designed to demonstrate a protective action of anti-parasite antibody. Such tests are, as would be expected, successful in those diseases which induce a sterilizing immune response-such as rodent trypanosomiasis, rodent malaria and cutaneous leishmaniasis. In other protozoal diseases and in helminth infections attempts to transfer protection with immune serum or cells have not been very successful; the few unequivocal results have required high doses of antiserum in relation to parasite numbers (for example, in human malaria and African trypanosomiasis).
Parasiticidal antibody has been revealed by in vitro assays in a wider range of infections and the mechanisms of immunity have been analysed in some detail. Antibodies which damage or kill parasites in vitro are found in malaria, African trypanosomiasis, schistosomiasis and nematode infections, yet all of these diseases produce a non-sterilizing immunity in vivo.
As a general rule, therefore, parasites effectively sensitize the host and yet may continue to survive for long periods. The way these organisms evade the potentially lethal consequences of immunization is a matter of fundamental biological interest. It is also of great practical importance for many aspects of immunology, including the imniunoprophylaxis of parasitic disease and the immunotherapy of neoplasms.
DISCUSSION
Discussion
Targett: I should like to question your division of the manifestations of acquired immunity into these three conditions : no clinical immunity, clinical resistance with survival of parasites, and sterile immunity. As you mentioned, it seems that in man cutaneous leishmaniasis is the most important example in the last group and you also included some of the rodent parasites, both trypanosomes and malaria parasites. I have been working with some of these and initially thought that there was a sterile immunity. However, with one trypanosome, Trypanosoma musculi, a natural parasite of the mouse which is related to T. lewisi, the parasites do survive in animals that are immune to further challenge; we found them in the vasa recta of the kidney (Viens et al. 1972) . We have evidence too that the same may be true in Plasmodium berghei yoelii infections in mice (A. N. Jayawardena & G. A. T. Targett, unpublished findings). 1 wonder whether there is a true sterile immunity in any parasite infection, or is it just that we have not looked properly?
Cohen: I was simply summarizing the literature on this point. Dr A. Corradetti did exhaustive tests on P. berghei in rats and satisfied himself that there was sterile immunity. This problem illustrates the important general point that conclusions depend on the species and strain of parasite used. Many laboratory organisms were removed from their native haunts years ago and have been kept frozen or propagated through experimental animals for so long that their relationship to the naturally occurring infection is unknown. This is one source of confusion. I don't question what you say but nor do 1 question Corradetti's conclusion.
Coombs: This problem is not so different from that of immunity in virus diseases: it is impossible to be absolutely certain that the last virus has gone. But would you deny that there may be such a thing as sterile immunity with these parasites, Dr Targett?
Targett: No, but since there are situations where we had assumed a sterile immunity, and this has been disproved, we should reconsider the possibility that there may be parasites somewhere in the body in other such situations.
Urquhart: We should avoid giving the impression that parasites survive in all immunized hosts. I wonder if Professor Cohen was being rather pessimistic? For example, in his category of 'no clinical immunity' he included 'many nematodes'. In experimental nematode infections there are many examples of a strong acquired immunity, and among parasitic diseases of domestic animals a similar situation occurs (see review by Jarrett & Urquhart 1971). One example is Dictyocaulus viviparus, the lungworm of cattle, which is very common in Europe. Once the primary infection, usually acquired in calfhood, is
